Lilly Adds $20M To Investment In Chinese Drugmaker

Law360, Los Angeles (June 12, 2012, 6:57 PM EDT) -- Eli Lilly & Co. plans to increase its investment in Chinese generic and specialty pharmaceutical manufacturer Novast Laboratories Ltd. by $20 million, the Indianapolis-based pharmaceutical giant announced Tuesday, saying the equity investment will help it build a portfolio of Lilly-branded generics in China.

“In Lilly's emerging markets business, we are focused on providing patients with innovative medicines from our own pipeline, as well as select Lilly-branded generic medicines that meet our quality standards,” Lilly’s president of emerging markets Jacques Tapiero said Tuesday. “The additional manufacturing capabilities...
To view the full article, register now.